Standout Papers

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonist... 2023 2026 2024103
  1. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria (2023)
    Brendon L. Neuen, Hiddo J.L. Heerspink et al. Circulation

Immediate Impact

3 by Nobel laureates 16 from Science/Nature 71 standout
Sub-graph 1 of 22

Citing Papers

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
2025 Standout
Digital colloid-enhanced Raman spectroscopy by single-molecule counting
2024 StandoutNature
1 intermediate paper

Works of Robert A. Fletcher being referenced

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
2023 Standout
A method to determine collection efficiency of particles by swipe sampling
2008

Author Peers

Author Last Decade Papers Cites
Robert A. Fletcher 477 150 368 560 397 76 1.9k
A. D’Alessio 631 7 673 856 273 73 1.5k
Alexander Bergmann 246 20 95 232 717 119 2.9k
Thorsten Streibel 794 11 215 182 212 104 2.5k
Masato Mikami 760 3 564 492 277 143 2.5k
Cari S. Dutcher 760 12 290 212 304 83 2.1k
Daniel Ferry 628 3 93 186 669 71 1.9k
Andrew Freedman 752 18 93 51 429 94 2.1k
Paul E. Schrader 697 457 794 383 39 1.4k
Konstantin Siegmann 367 188 298 358 56 1.6k
Akira Miyoshi 951 2 649 1020 678 99 2.5k

All Works

Loading papers...

Rankless by CCL
2026